DISEASE CHARACTERISTICS:

• Histologically confirmed clear cell renal cell carcinoma

  • Primary or metastatic lesion
  • Less than 25% of any other histology (papillary, chromophobe, or oncocytic)

• Sufficient pathology material available for diagnostic review

  • Core-needle biopsy allowed
  • No fine-needle aspirations as only source for diagnosis
• Measurable metastatic disease
• Not curable by standard radiotherapy or surgery

• Prior nephrectomy required, with the following exceptions:

  • Primary tumor ≤ 5 cm
  • Extensive liver metastases (> 30% of liver parenchymal) or multiple (> 5) bone metastases
• No history or clinical evidence of CNS disease, including primary brain tumor or brain metastases

PATIENT CHARACTERISTICS:

• ECOG performance status 0-1
• Life expectancy > 3 months
• WBC ≥ 3,000/mm³
• Absolute granulocyte count ≥ 1,200/mm³
• Platelet count ≥ 100,000/mm³
• Hemoglobin ≥ 9.0 g/dL (transfusions allowed)
• Creatinine ≤ 1.5 times upper limit of normal (ULN) OR creatinine clearance ≥ 55 mL/min
• Bilirubin ≤ 1.5 times ULN
• AST/ALT ≤ 2.5 times ULN (5.0 times ULN in the presence of liver metastases)
• INR ≤ 1.5 and aPTT normal
• Fasting cholesterol < 350 mg/dL
• Fasting triglycerides < 400 mg/dL
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception during and for 6 months after completion of study treatment
• No seizures not controlled with standard medical therapy
• No stroke within the past 12 months
• No other malignancies within the past 5 years except basal cell skin cancer, squamous cell skin cancer, carcinoma in situ of the cervix, or ductal or lobular carcinoma in situ of the breast
• No history of allergic reactions attributed to Chinese hamster ovary cell products, other recombinant human antibodies, or compounds of similar chemical or biologic composition to sorafenib tosylate, temsirolimus, or bevacizumab
• No history of bleeding diathesis or coagulopathy
• No condition that impairs ability to swallow pills
• No significant traumatic injury within the past 28 days

• No clinically significant cardiovascular disease, including any of the following:

  • Uncontrolled hypertension

    • Blood pressure must be ≤ 150/100 mm Hg on a stable antihypertensive regimen
  • Myocardial infarction or unstable angina within the past 6 months
  • New York Heart Association class II-IV congestive heart failure
  • Serious cardiac arrhythmia requiring medication
  • Unstable angina pectoris
  • Peripheral vascular disease ≥ grade 2
• No serious, nonhealing wound, ulcer, or bone fracture

• No significant proteinuria

  • If urine protein:creatinine ratio > 0.5, 24-hour urine protein must be < 1,000 mg
• No uncontrolled intercurrent illness including, but not limited to, ongoing or active infection requiring parental antibiotics on day 0 or psychiatric illness or social situations that would preclude compliance with study requirements

PRIOR CONCURRENT THERAPY:

• See Disease Characteristics
• No more than 1 prior regimen containing vaccine- or cytokine-based immunotherapy for advanced disease
• No prior antiangiogenic therapy including, but not limited to, sunitinib malate, ZD6474, or VEGF Trap
• No prior bevacizumab, mTOR inhibitors (including, but not limited to, temsirolimus), or sorafenib tosylate
• Prior thalidomide or interferon alfa allowed as adjuvant therapy or for stage IV disease
• More than 4 weeks since prior immunotherapy
• More than 2 weeks since prior radiotherapy and recovered
• More than 4 weeks since prior major surgery or open biopsy
• No concurrent major surgery
• No concurrent or recent full-dose anticoagulants or thrombolytic agents (unless required to maintain patency of pre-existing or permanent indwelling IV catheters)

• No concurrent cytochrome P450 enzyme-inducing drugs including any of the following:

  • Phenytoin
  • Carbamazepine
  • Phenobarbital
  • Rifampin
• No concurrent combination antiretroviral therapy for HIV-positive patients
• No other concurrent anticancer therapies or investigational agents
• No concurrent prophylactic hematopoietic colony-stimulating factors